Research programme: sustained-release therapeutics - SKS Ocular

Drug Profile

Research programme: sustained-release therapeutics - SKS Ocular

Latest Information Update: 06 Jun 2014

Price : $50

At a glance

  • Originator SKS Ocular
  • Class Proteins; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Eye disorders; Glaucoma

Most Recent Events

  • 02 Jun 2014 SKS Ocular has been acquired by Ohr Pharmaceutical
  • 15 May 2014 Preclinical trials in Eye disorders in USA before May 2014 (Intraocular)
  • 15 May 2014 Preclinical trials in Glaucoma in USA before May 2014 (Subconjunctival)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top